Literature DB >> 20659423

Striated muscle angio-adaptation requires changes in Vasohibin-1 expression pattern.

Marina Kishlyansky1, Jovana Vojnovic, Emilie Roudier, Charlotte Gineste, Simon Decary, Paul Forn, Raynald Bergeron, Dominique Desplanches, Olivier Birot.   

Abstract

Vasohibin-1 (VASH-1) was recently identified as a negative feedback regulator of angiogenesis. Here, we analyzed how the expression of the two active anti-angiogenic VASH-1 isoforms p36 and p42 was altered during physiological and pathological muscle angio-adaptation. Our results showed that VASH-1 protein expression was muscle-type specific, with higher levels detected in less vascularized muscles. In rat plantaris and heart muscles, the expression of VASH-1 protein was decreased in response to exercise training, a physiological pro-angiogenic stimulus leading to muscle capillary growth. Interestingly, expression patterns for p36 and p42 were different between plantaris and heart muscles. Next, we analyzed the time-course expression of VASH-1 isoforms in rat soleus muscles subjected to hindlimb unloading, a model that induces muscle capillary regression. Both p36 and p42 isoforms were increased, a signal in favor of some vessel destabilization and regression. Finally, we investigated VASH-1 expression in plantaris muscles from Zucker Diabetic Fatty rats (ZDF) that develop obesity and type-2 diabetes associated with a loss of capillaries in skeletal muscle. VASH-1 expression was higher in sedentary ZDF rats when compared to lean animals, suggesting its potential role during capillary regression. Interestingly, a physiological VASH-1 level was efficiently restored in spontaneously active ZDF animals where muscle capillarization was preserved. In conclusion, our results bring evidence that endogenous VASH-1 isoforms p36 and p42 are key actors of physiological and pathological muscle angio-adaptation. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20659423     DOI: 10.1016/j.bbrc.2010.07.076

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

1.  Vasohibin1, a new mouse cardiomyocyte IRES trans-acting factor that regulates translation in early hypoxia.

Authors:  Fransky Hantelys; Anne-Claire Godet; Florian David; Florence Tatin; Edith Renaud-Gabardos; Françoise Pujol; Leila H Diallo; Isabelle Ader; Laetitia Ligat; Anthony K Henras; Yasufumi Sato; Angelo Parini; Eric Lacazette; Barbara Garmy-Susini; Anne-Catherine Prats
Journal:  Elife       Date:  2019-12-09       Impact factor: 8.140

Review 2.  The vasohibin family: a novel family for angiogenesis regulation.

Authors:  Yasufumi Sato
Journal:  J Biochem       Date:  2012-10-25       Impact factor: 3.387

Review 3.  Exercise training and peripheral arterial disease.

Authors:  Tara L Haas; Pamela G Lloyd; Hsiao-Tung Yang; Ronald L Terjung
Journal:  Compr Physiol       Date:  2012-10       Impact factor: 9.090

4.  Effects of pleiotrophin overexpression on mouse skeletal muscles in normal loading and in actual and simulated microgravity.

Authors:  Giulia Maria Camerino; Sabata Pierno; Antonella Liantonio; Michela De Bellis; Maria Cannone; Valeriana Sblendorio; Elena Conte; Antonietta Mele; Domenico Tricarico; Sara Tavella; Alessandra Ruggiu; Ranieri Cancedda; Yoshinobu Ohira; Daniela Danieli-Betto; Stefano Ciciliot; Elena Germinario; Dorianna Sandonà; Romeo Betto; Diana Conte Camerino; Jean-François Desaphy
Journal:  PLoS One       Date:  2013-08-28       Impact factor: 3.240

Review 5.  Advances and challenges in skeletal muscle angiogenesis.

Authors:  I Mark Olfert; Oliver Baum; Ylva Hellsten; Stuart Egginton
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-11-25       Impact factor: 4.733

Review 6.  The roles of vasohibin and its family members: Beyond angiogenesis modulators.

Authors:  Hua Du; Jing Zhao; Ling Hai; Jing Wu; Hua Yi; Yonghong Shi
Journal:  Cancer Biol Ther       Date:  2017-09-08       Impact factor: 4.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.